BRIEF-Vaximm AG Reports Phase 2A Results For VXM01 And Avelumab Combo In Glioblastoma

Reuters
26 Mar
BRIEF-Vaximm AG Reports Phase 2A Results For VXM01 And Avelumab Combo In Glioblastoma

March 26 (Reuters) - OSR Holdings Inc OSRH.O:

  • VAXIMM AG, AN OSR COMPANY, ANNOUNCES RESULTS FROM PHASE 2A TRIAL OF VXM01 AND AVELUMAB COMBINATION THERAPY IN GLIOBLASTOMA

  • VAXIMM AG - PHASE 2A TRIAL SHOWS GOOD SAFETY AND TOLERABILITY PROFILE

  • VAXIMM AG - NO SERIOUS ADVERSE EVENTS ATTRIBUTED TO VXM01

  • VAXIMM AG- DECREASED TUMOR SIZE OBSERVED IN RESPONDING PATIENTS

Source text: ID:nPn8QQQdYa

Further company coverage: OSRH.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10